safe harbor for forward-looking statements/media... · assessor-blind, parallel two-arm, controlled...
TRANSCRIPT
1
Safe harbor for forward-looking statements
This presentation contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,”
“estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and are not intended to be
guarantees of future events or performance. If our underlying assumptions turn out to be incorrect,
or if certain risks or uncertainties materialize, actual results could differ materially from the
expectations and projections expressed or implied by our forward-looking statements.
Factors that may cause such differences can be found in our most recent Form 10-K and Forms
10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk
Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to
place undue reliance on any of our forward-looking statements. We disclaim any intention or
obligation to publicly update or revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which they may be based, or that may
affect the likelihood that actual results will differ from those contained in the forward-looking
statements.
© 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
2
Disclaimers
Product Approvals
This presentation includes discussion of products that have not been approved or cleared by the U.S.
Food and Drug Administration (FDA) and are not available for sale in the U.S.
All future product approval and launch dates are based on estimates of completion of regulatory
submissions, review and approval or clearance, as well as other business considerations.
Market Estimates
Unless noted otherwise, all references to market sizes, market share positions, and market growth rates
are BSC internal estimates.
Non-GAAP Financial Measures
For reconciliations of non-GAAP financial measures used in these presentations to the most directly
comparable GAAP figures, please refer to the footnotes referenced in this presentation and the Investor
Relations section of our website at www.bostonscientific.com.
© 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
3
Peripheral Interventions Overview
Jeff Mirviss SVP and Global President
Dave Van Horne Vice President, Global Marketing
Boston Scientific Peripheral Interventions
PI-366203-AA © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
4 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
BSX Peripheral Interventions
• Market leader: #1 market share with strong positions in key growth categories
• Patient Impact: Large, under-treated and under-diagnosed patient populations
• Clinical Demand: Unmet clinical needs provide significant opportunity to innovate
2015
Market BSX
Size Growth Share Position Growth
$4.5B +4-6% #1 +13%*
* Excluding the impacts of .foreign currency of (7)%, Peripheral Inventions net sales grew 6% on a reported basis
5 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
BSX PI Strategy
Build a Broad, Differentiated and Complete Portfolio in High Impact Areas
Peripheral
Arterial Disease
Venous
Disease
Interventional
Oncology
• >200m patients globally
• Est. $3.75B global market
• +4-5% growth
− Rapid DE adoption
− Shift to endovascular vs open
• >1.5m w/VTE in US & Europe
• Est. $500m global market
• +8-10% growth
− Physician interest very high
− New evidence (ATTRACT)
• >700K w/liver cancer annually
• Est. $1.5B global market
• +5-6% growth
− Expense/side effects of chemo
− Emerging markets opportunity
DE = Drug-Elution PAD = Peripheral Artery Disease VTE = Venous Thromboembolism (DVT and Pulmonary Embolism)
6 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
Broadest Portfolio of Technology Solutions
PTA balloons Stents
Crossing
Atherectomy
Embolic spheres
Drainage catheters
Thrombectomy
Microcatheters & guidewires
Detachable & pushable embolization coils
Vena Cava filters
DCB DES
Carotid stents
Cutting balloon
Guidewires
Guidesheaths
Tumor ablation
Peripheral
Arterial Disease
Venous
Disease
Interventional
Oncology
7
Interventional Oncology: Global Growth Opportunity
CeloNova Embolics
• Examining chemoembolization
• Currently enrolling in SOLACE Trial
• Randomized, controlled trial
examining the use of ONCOZENE™
Microspheres* loaded with doxorubicin
in the treatment of unresectable, locally
advanced hepatocellular carcinoma
Clinical Research Future Technologies**
• Completed acquisition in Dec 2015
• Includes both ONCOZENE™ and
EMBOZENE™ (bland) Microspheres
• Clinical: UFE/PAE Indications
• New embolization technologies
• Liver cancer, oral cancer; anywhere
accessible via vascular system
*CAUTION: Investigational device in the U.S.
and is not available for sale.
Expand IO Portfolio into Areas of Unmet Need
** Concept technology, Not available for sale.
UFE = Uterine Fibroid Embolization PAE = Prostate Artery Embolization
© 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
8
Venous Disease: The Next Frontier for Peripheral Intervention
Angiojet ZelanteDVT
• Preparing for ATTRACT data – 2017
• Drive patient awareness:
ClearingtheClot.com &
World Thrombosis Day 10/13/16
• Referring physician engagement
Accelerate Adoption
• Built on category-leading AngioJet
Thrombectomy System
• Large-diameter, dedicated DVT catheter
• 4x power of previous AngioJet catheters
• Complete portfolio could include
thrombectomy, filters, CDT, PE, stents
• Unmet clinical need: chronic clot, PTS
• Equity investments: Veniti, InterVene
* CAUTION: Not available for use or sale in the U.S..
Build on Category-Leading AngioJet Platform
to Create Complete Venous Portfolio
Portfolio Expansion
DVT = Deep Vein Thrombosis CDT = Cather-Delivered Thrombolysis PE = Pulmonary Embolism PTS = Post Thrombotic Syndrome © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
9 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
ATTRACT Trial Overview
• NIH-funded, Phase III, multicenter, randomized, open-label,
assessor-blind, parallel two-arm, controlled clinical trial.
• 692 patients at 30-60 centers
• Determining if the use of Pharmamechanical CDT (e.g.,
AngioJet) in acute DVT reduces occurrence of post
thrombotic syndrome (PTS) over 24 months
• Includes both clinical and economic outcomes
• Expect data H1:2017
• Trellis™-8
• AngioJet™ System
• Catheter-Directed Thrombolysis
• Anticoagulant therapy
• Elastic compression stockings
Treatment Arm Control Arm
ATTRACT Trial Data Could Drive Increased Utilization of AngioJet™ System
10 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
VENITI Equity Investment
Boston Scientific and VENITI, Inc. have entered into an agreement by which
Boston Scientific has made a $25M investment in VENITI
• Investment makes Boston Scientific the largest individual
shareholder in VENITI
• VENITI developing the VICI Venous Stent® System, a nitinol-
based stent designed specifically for venous application
• CE Mark received in 2013
• Currently enrolling in VIRTUS IDE study
• Chronic venous insufficiency affects more than 20 million adults
across the United States and Western Europe
• Venous stents may be used in many venous procedures alongside
other endovascular technologies (e.g., thrombectomy, imaging
catheters, balloons)
• Venous physiology demands dedicated stent design: typically
larger diameter, designed for strength and flexibility
11
Drug-Eluting Technologies: Improving Patency in the Lower Limbs
Ranger™ DCB*
• CE Mark / launched in 2016
• 24-month results from MAJESTIC:
92.5% Freedom from clinically
driven TLR at 24 months
• Currently enrolling in IMPERIAL
IDE Study
Eluvia ™ DES*
Drug-Elution BTK**
• CE Mark / launched in 2014
• 6-month results from RANGER
SFA study: 94.4% Freedom from
clinically relevant TLR at 6 months
• Interim data from the Ranger All-
Comer Registry: 91.9% freedom
from TLR and a primary patency of
91.1% at 6 months
• Significant unmet clinical need
• Longer, more calcified lesions
• DCB and DES applications
• BSC research has begun
• Assessing clinical pathway
* CAUTION: Not available for use or sale in the U.S..
Compelling Portfolio of State-of-the-Art Technologies
** Concept technology, Not available for sale. TLR = Target Lesion Revascularization © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
12 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
MAJESTIC Trial Results: CIRSE 2016
13
MAJESTIC Trial:
Efficacy and Safety Data
At risk: 56 53.5 36.5
Time Post-procedure (months)
Cum
ula
tive
TL
R-F
ree
Rate
24-Month Freedom from TLR Kaplan-Meier Estimate
Efficacy
• 2-year Freedom from TLR: 92.5% (7.5% TLR)
– KM estimate: 91.3%
– Highest-reported TLR-free rate among SFA stent trials
• Only 2 new TLRs between 1 and 2 years
Safety Profile
• 7.5% (4/53) MAE rate
• No target limb major amputations
Stent Integrity
• No stent fractures observed by the core lab
TLR = target lesion revascularization; MAE = major adverse events
91.3%
12 Months 24 Months
Primary Patencya 96.4% 78.2%
Note: Kaplan-Meier Estimates. aDuplex ultrasound peak systolic velocity ratio ≤2.5 and absence of TLR or bypass.
© 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
14 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
Ranger SFA Trial Results: CIRSE 2016
15
• Similar Adverse Event and Serious Adverse
Event rates between groups
No target limb amputations
1 death within 6 months (control group)
0%
20%
40%
60%
80%
100%
0 100 200 300 400TL
R-F
ree
Rat
e
Time Since Procedure (days)
Freedom From TLR at 6 Months*
Freedom from TLR of 94.4% at 6 months, with significantly less late lumen loss vs. PTA
Ranger DCB PTA
Late Lumen Loss
Ranger -0.16
Late Lumen Loss (mm)
*Kaplan-Meier Analysis
*
Ranger SFA Trial:
Efficacy & Safety Data
TLR = target lesion revascularization; MAE = major adverse events © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
16 © 2016 Boston Scientific Corporation or its affiliates. All rights reserved.
Summary
• Peripheral vascular represents a large, under-diagnosed &
under-treated market
– BSX building a broad, differentiated and complete portfolio in high impact areas
– Focus on areas of greatest need and opportunity: Drug-Elution, Venous and Cancer
• Technologies designed to enable better outcomes and
reduce healthcare costs
– Eluvia Drug-Eluting SFA Stent – IMPERIAL IDE Trial currently enrolling
– Ranger DCB – Continue to work to bring to additional markets
– Thrombectomy – ATTRACT trial expected to drive significant growth
– Interventional Oncology – Strong portfolio & pipeline; opportunity in emerging markets